EVENTS
MARK YOUR CALENDAR: UPCOMING JOINT MASSEP AND GBMSDG MEETING, December 3rd, 2025, 5pm to 8:30pm
- Topic: The Role of Analytical Chemistry in PFAS Environmental Issues - Past, Present and Future by Dr. Charles Powley.
- Location: Northeastern BATL facility at 147 South Bedford St., Burlington, MA.
- Please note: Due to site security restrictions, registration will close on November 26th and there will be no door sales.
- Admission fee is $12.51 for professional members, free admission for students
- Scan the QR Code or visit the EventBrite link below for schedule and registration .
PLEASE EMAIL TO treasurer.massep@gmail.com IF YOU HAVE CANCELLATIONS OR LAST-MINUTE CHANGES. VIRTUAL ATTENDANCE IS STILL UNLIMITED, BUT WE WILL NOT BE ABLE TO SEND YOU A MEETING LINK AFTER NOON ON THURSDAY, NOVEMBER 13th, SO PLEASE ACT ACCORDINGLY AND LET US KNOW IF YOU WANT TO LISTEN TO THIS SEMINAR BEFORE IT IS TOO LATE!
November 13th, 2025 MEETING at Waters IMMERSE LAB in Cambridge
FOLLOW THE LINK ON THE "JOIN US" PAGE TO JOIN OUR MAILING LIST
-
-
-
- SPEAKER: Lavelay Kizekai, Waters Corporation
-
- TITLE: From GLP's to LNP's: Recent Advances in Size-based Separations.
-
- ABSTRACT:
- Size exclusion chromatography (SEC) has long been a cornerstone technique for characterizing biotherapeutic drugs, particularly for detecting size variants that can impact efficacy or trigger immunogenic responses. High and low molecular weight species are now recognized as critical quality attributes, making their accurate quantitation essential for drug development and manufacturing. However, the latest generation of biotherapeutics—such as fatty acid–modified peptides, viral vectors, and nanoparticle formulations—introduces new analytical challenges. Design features that enhance therapeutic performance often increase secondary interactions, leading to poor recovery and resolution in SEC. Mitigation strategies, while helpful, can introduce conformational variability, stability concerns, or method-induced artifacts. To address these complexities, a new class of SEC columns has been developed, featuring highly inert particle and hardware surfaces combined with purpose-tuned pore diameters. When paired with best practices and advanced complementary detection techniques like multi-angle light scattering (MALS) and mass spectrometry (MS), these columns deliver robust, reliable characterization of complex modalities. This presentation will highlight the capabilities of next-generation SEC columns and emphasize the importance of optimized workflows. We will demonstrate how these advancements enable significant improvements in the analysis of size variants across a broad range of biotherapeutics and gene therapies—from peptides to large lipid nanoparticles and viral vectors—ultimately supporting the development of transformative medicines.
SPEAKER:
- Lavelay Kizekai is a principal scientist at Waters Corporation. His primary area of focus is biomolecule separations using size-exclusion chromatography (SEC). He was a core member of the team that recently brought to market a column suited to platform methods for monoclonal antibodies and antibody-drug conjugates. He is currently leveraging these SEC technologies and newer breakthroughs for the characterization of gene-based therapeutics by multiangle light scattering.
-
- The link above will open your default email client. Simply put "IN PERSON" or "ONLINE" in the subject line and hit "Send" to register.
- If your security software blocks the mailto: browser requests, please email to treasurer.massep@gmail.com with the appropriate subject line and we will reply with a confirmation.
-
